These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 19549510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.
    Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA.
    J Pharmacol Exp Ther; 2010 Jun; 333(3):748-57. PubMed ID: 20194526
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
    Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrié P, Scatton B.
    J Pharmacol Exp Ther; 2002 Aug; 302(2):731-41. PubMed ID: 12130738
    [Abstract] [Full Text] [Related]

  • 7. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system.
    Khawaja XZ, Smith DL, Nawoschik SP, Zhang J, Dunlop J, Dilks DW, Olsen M, Schechter LE.
    J Neurochem; 2006 Jul; 98(1):134-45. PubMed ID: 16805803
    [Abstract] [Full Text] [Related]

  • 8. Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).
    Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE.
    J Pharmacol Exp Ther; 2008 Apr; 325(1):134-45. PubMed ID: 18182558
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist.
    Stean TO, Hirst WD, Thomas DR, Price GW, Rogers D, Riley G, Bromidge SM, Serafinowska HT, Smith DR, Bartlett S, Deeks N, Duxon M, Upton N.
    Pharmacol Biochem Behav; 2002 Apr; 71(4):645-54. PubMed ID: 11888556
    [Abstract] [Full Text] [Related]

  • 11. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M, Zhang L, Rotondo A, Sun H, Morales M.
    Synapse; 2003 Dec 15; 50(4):303-13. PubMed ID: 14556235
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T, Komada T, Sugimoto H, Suzuki K, Ohmi T, Kimura N, Naganeo R, Nakata E, Nakatani K, Toga T, Eda H, Sakakibara M.
    Eur J Pharmacol; 2009 May 01; 609(1-3):5-12. PubMed ID: 19285067
    [Abstract] [Full Text] [Related]

  • 13. Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors.
    Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P.
    Eur J Pharmacol; 2004 Jul 14; 495(2-3):97-102. PubMed ID: 15249157
    [Abstract] [Full Text] [Related]

  • 14. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A, Arbus C, Nuss P, Garay RP, Neliat G, Hameg A.
    Eur J Pharmacol; 2008 Jan 14; 578(2-3):142-7. PubMed ID: 17936750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
    Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM.
    Br J Pharmacol; 1998 Dec 14; 125(7):1413-20. PubMed ID: 9884068
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
    Jordan S, Chen R, Koprivica V, Hamilton R, Whitehead RE, Tottori K, Kikuchi T.
    Eur J Pharmacol; 2005 Jul 11; 517(3):165-73. PubMed ID: 15985260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating.
    Schreiber R, Vivian J, Hedley L, Szczepanski K, Secchi RL, Zuzow M, van Laarhoven S, Moreau JL, Martin JR, Sik A, Blokland A.
    Eur Neuropsychopharmacol; 2007 Mar 11; 17(4):277-88. PubMed ID: 16989988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.